Drucy Borowitz

Dr. Drucy Borowitz

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
BMBaha Moshiree
Baha Moshiree
AFAlvin Jay Freeman
Alvin Jay Freeman
PVPhuong T. Vu
Phuong T. Vu
UKUmer Khan
Umer Khan
CUCarmen Ufret-Vincenty
Carmen Ufret-Vincenty
MSMeghana Nitin Sathe
Meghana Nitin Sathe

1 July 2021 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
SHSara Henen
Sara Henen
CDChristine Denton
Christine Denton
JTJeff Teckman
Jeff Teckman
DBDrucy Borowitz
Drucy Borowitz
DPDhiren Patel
Dhiren Patel
Gastrointestinal manifestations in patients with cystic fibrosis (CF) are extremely common and have recently become a research focus. Gastrointestinal (GI) dysfunction is poorly understood in the CF population, despite many speculations including the role of luminal pH, bacterial overgrowth, and abnormal microbiome. Nevertheless, dysmotility is emerging as a possible key player in CF intestinal symptoms. Our review article aims to explore the sequelae of defective cystic fibrosis transmembrane conductance regulator (CFTR) genes on the GI tract as studied in both animals and humans, describe various presentations of intestinal dysmotility in CF, review newer diagnostic motility techniques including intraluminal manometry, and review the current literature regarding the potential role of dysmotility in CF-related intestinal pathologies.

13 January 2021 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
AFAlvin Jay Freeman
Alvin Jay Freeman
MSMeghana Sathe
Meghana Sathe
EAEnid Aliaj
Enid Aliaj
DBDrucy Borowitz
Drucy Borowitz
BFBarbra Fogarty
Barbra Fogarty
BMBaha Moshiree
Baha Moshiree

1 March 2019 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
KJKaiyu Jiang
Kaiyu Jiang
KPKerry Poppenberg
Kerry Poppenberg
LWLaiping Wong
Laiping Wong
YCYanmin Chen
Yanmin Chen
DBDrucy Borowitz
Drucy Borowitz
JJJames N. Jarvis
James N. Jarvis

11 June 2022 in Pancreas
Verified
Journal Article
Open access
DBDrucy Borowitz
Drucy Borowitz
NANell Mls Aronoff
Nell Mls Aronoff
LCLinda C. Cummings
Linda C. Cummings
AMAsim Maqbool
Asim Maqbool
AMAndrew E. Mulberg
Andrew E. Mulberg
Objectives: We sought data on the validity, reliability, responsiveness, and feasibility of the coefficient of fat absorption (CFA) as a measure of pancreatic enzyme replacement therapy (PERT) efficacy in people with cystic fibrosis (pwCF) and reviewed the literature for alternative measures. Methods: We searched PubMed for the Medical Subject Heading cystic fibrosis and the key words cystic fibrosis, fat absorption, CFA, and fecal fat imbalance; historical articles; and citations in bibliographies. Results: The lower the CFA, the greater its variability; thus, it is less variable in healthy individuals who have higher CFA than pwCF. In addition, the test-retest values for CFA are more variable in pwCF than the general population. There is no correlation between CFA and body mass index or PERT dose but CFA is related to gastrointestinal signs and symptoms. Research-quality CFA studies are expensive, time consuming, and odious to pwCF and research staff. Sparse stool tests, breath tests, and blood tests of fat absorption have been studied as potential alternatives to CFA to measure PERT efficacy. Conclusions: Based on the evidence, we conclude that CFA as a measure of the efficacy of PERT is more of a “coal standard” than a gold standard; developing suitable alternatives should be a priority.

22 January 2001 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
DBDrucy Borowitz
Drucy Borowitz
DADouglas Armstrong
Douglas Armstrong
FCFrank Cerny
Frank Cerny